LQCL2308 - CMLE - ARGATROBAN, BIVALIRUDIN, DABIGATRAN, AND OTHER NOVEL ANTICOAGULANTS IN THE COAGULATION LABORATORY-ARGATROBAN, BIVALIRUDIN, DABIGATRAN, AND OTHER NOVEL ANTICOAGULANTS IN THE COAGULATION LABORATORY

ARGATROBAN, BIVALIRUDIN, DABIGATRAN, AND OTHER NOVEL ANTICOAGULANTS IN THE COAGULATION LABORATORY

Pdf Summary

The document discusses the challenges in monitoring anticoagulation therapy, particularly focusing on new anticoagulants like argatroban, bivalirudin, and dabigatran. These drugs can interfere with lab tests and complicate monitoring. It outlines how they affect various coagulation tests, the importance of identifying these interferences, and alternative monitoring options. Additionally, it explains the difficulties in transitioning patients from intravenous anticoagulants to oral warfarin. The text emphasizes the need for awareness among clinicians and labs regarding these interferences and suggests using tests like thrombin time and anti-Xa assays to detect specific anticoagulants. The implications of these new anticoagulants on laboratory testing, patient management, and the importance of accurate monitoring are highlighted throughout the document.

Keywords

anticoagulation therapy

argatroban

bivalirudin

dabigatran

coagulation tests

interferences

monitoring options

intravenous anticoagulants

warfarin transition

thrombin time